Search
Clobutinol
go.drugbank.com/drugs/DB09004ApprovedWithdrawnClobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Chlorophyll B
go.drugbank.com/drugs/DB04506ExperimentalIt has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. … (From Dorland, 27th ed)
Uprifosbuvir
go.drugbank.com/drugs/DB15206InvestigationalC Genotype (GT)1 and GT2 Infection (MK-3682-011)). … Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis
Estradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. … [DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalManufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have … a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
Balsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approvedIt is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676]. … [F117] Under the FDA, balsam of Peru is considered as an inactive ingredient to be used for approved drug products[L2878] as well as an approved food additive under the categorization of generally recognized
Synonyms: bálsamo de PerúMixtures: DERIVERIN MERHEM, 25 G, Arnica De LA AbuelaPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like nivoluma...
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsTechnetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedIt is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label]. … It may be administered via subcutaneous, intradermal, subareolar, or peritumoral injection, depending on the tutor location and planned injection technique [FDA Label].
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigationalinhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting the secondary solvent-front mutation _G2032R_ is 400 … It is targeted against ROS1, including resistant mutant forms, and shows some inhibitor activity against tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC.
Bufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnBufexamac was also withdrawn by the EMA in April 2010. … It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids.